The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.50
Bid: 20.00
Ask: 21.00
Change: -0.25 (-1.20%)
Spread: 1.00 (5.00%)
Open: 20.75
High: 20.75
Low: 20.50
Prev. Close: 20.75
IOF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Results

12 May 2009 07:00

RNS Number : 0724S
Iofina PLC
12 May 2009
 



 

12th May 2009

Iofina plc

 ("Iofina" or "the Company")

Iofina Reports Audited Full Year Financials

The directors of Iofina are pleased to announce its preliminary results for the year ended 31 December 2008. 

Highlights of 2008

- Successful IPO and fundraising in May 2008 raising £15.1 million

- Completed field facilities with drilling rig delivered and buildings completed with production facilities installed

- Completed expansion of pipeline, opening additional Atlantis Prospect acreage for field development 

- Fully funded through to cash generation

Highlights of 2009

- Commercial gas production started

- High pressure readings indicate gas and brine production could be ahead of levels previously indicated

- Additional c.230,000 acres acquired within the Atlantis Prospect, which includes 17 shut-in wells that will immediately be brought into gas production

- Successful fundraising in February 2009 raising £5 million to fund development of Iofina Chemicals into the higher margin iodine derivatives market

- Exploring further opportunities to work with US Oil & Gas producers to tap unexploited iodine from their brine streams utilizing Wellhead Extraction Technology® (WET®)

Dr David Schneider, Chief Executive Officer, commented:

"2008 was a year of significant progress for the Company as we achieved a successful listing on the AIM market which provided us with the funds to proceed with our ambitious strategy for growth.

As set out at the time of IPO, Iofina has always been focused on generating income from the extraction of iodine using its unique WET technology. We are now close to delivering iodine into the US market, and through the development of the Iodine Derivatives business, expect to derive stronger margins.  We continue to be very excited about Iofina's prospects in 2009 and we look forward to providing further updates on future developments."

For further information, please contact: 

Lance Baller, CFO

Iofina plc

Tel: +44(0)20 3006 3135

 

Nominated Adviser:

James Harris/Angela Peace

Strand Partners Limited

Tel: +44(0)20 7409 3494

 

Broker:

Rory Scott

Mirabaud Securities Limited

Tel: +44(0)20 7878 3360

 

Media Contact:

Chelsea Hayes/ Tara Owen-Smith

Pelham Public Relations

Tel: +44 (0)20 337 1523

 

  CHAIRMAN'S STATEMENT

Introduction

We are pleased to report that the Group made substantial progress in 2008. The first half of 2008 was a period of rapid development for Iofina, in terms of both the assets and financial resources of the Group. In May, the Company completed the admission of its ordinary shares to trading on the London Stock Exchange's AIM Market ("AIM"). The Company raised over £15.1 million (gross) in an oversubscribed placing of ordinary shares during an extremely difficult time in the financial markets with backing coming from a number of leading international institutional investors. The successful fund raising in such conditions illustrates, the depth, commitment and experience of our management team, the quality of our prospects and the wider opportunity we have to develop the business in the future. We are now well capitalized, allowing management to execute its aggressive growth strategy over the next few years, while ensuring costs are carefully managed. Iofina remains on track to be the lowest cost producer of Iodine.  

The second half of 2008 was focused on iodine and natural gas field development. To this end we completed the expansion of the pipeline by an additional nine (9) miles to the Iofina Express #1 pipeline which enabled the opening of additional Atlantis Prospect acreage to field development. We secured all the necessary company owned equipment for drilling, fracture stimulation, cementing, and pipeline excavation and in late October we took delivery of the Group's wholly owned drilling Rig #10 which was a new Versa-Drill® V-2095EXP. The first production wells in the Atlantis Prospect were drilled with this rig from the fourth quarter of 2008, albeit experiencing significant delays due to extreme weather. The iodine and gas separation buildings have been completed and the process facility and field laboratory installed. During 2008 we more than doubled our acreage position in Atlantis Prospect and in addition we acquired over 30,000 net acres within an area in south eastern Montana, which we named the Triton Prospect. Enhancements continue to be made to the Wellhead Extraction Technology® (WET®) which will result in higher iodine extraction recovery rates and lower operational costs. The Company ended the year with a strong balance sheet position with over £12.9million of cash and no further large infrastructure capital funding is expected.

In February 2009, the Company raised £5 million (before expenses) through a placing of 9,090,000 new ordinary shares of 1p each in the Company (the "Placing Shares"), at a price of 55p per share (the "Placing") to establish Iofina Chemical's entry into the iodine derivatives market. The Placing was priced at a 12% premium to the previous day's closing price. Despite extremely difficult capital market conditions, we were delighted by the response of both new and existing institutional investors who shared our excitement and vision with respect to vertically integrating Iofina into the iodine derivatives market. We believe vertical integration through both production and derivatives should result in significantly better margins for Iofina.  Additionally, this move will enhance Iofina's strategic position in the US where the large domestic blue chip end users of iodine derivatives currently rely heavily on imports from Chile and Japan.

With approximately £17million of net cash on the balance sheet upon the completion of the Placing, Iofina is fully funded to progress the Atlantis Prospect through to full development and positive cash flow generation, while at the same time moving Iofina Chemical into the iodine derivatives market. We have been in detailed discussions with a number of JV partners for the iodine chemical derivatives business and continue to assess potential acquisition targets.

Operational Update

I am pleased to announce that in the last 30 days the Company began production at our flagship Atlantis Prospect located in MontanaUSA. In the January 2009 drilling update it was announced that the initial flare testing had confirmed that gas volumes exceeded the anticipated rates and we continue to remain encouraged following additional testing and processing of early production data. More detailed gas production figures will be released in due course when stabilized flow rates are achieved and the iodine extraction from the brine stream commences. We experienced unexpected delays due to technical issues surrounding brine injection. However, following approval being obtained to inject at higher pressures and completion of fracture stimulation we are now successfully underway. 

Iofina continues to acquire leases for iodine and gas production whilst evaluating other similar opportunities in other parts of the United States. The price of natural gas on the NYMEX Henry-Hub Natural Gas market in the US has reduced from over $13 Mcf in July 2008 to the current price of $4.25 Mcf due to over supply from the newly drilled shale gas and declining industrial use resulting from the global recession. As at Friday, May 1, working gas in underground storage in the US was 1,918 billion cubic feet (Bcf), which is 23.3 percent above the 5-year (2004-2008) average and 34 percent above the average of 1.43 trillion cubic feet one year ago. While the current price of natural gas affects the Group we have looked for opportunities to capitalize on the recent weakness in order to build long term benefits for the Group.

Recognising this as an opportunity we have identified potential US oil and gas industry partners that may have iodine present in their existing brine streams which could benefit from working with Iofina. We have had several successful negotiations with these targeted producers and are currently obtaining brine samples that are being analyzed by our Kentucky technical center. Currently these large existing brine streams are being re-injected without the extraction of iodine. These producers had commercially viable fields on the oil and gas alone so any profit sharing that can be realized from the production of iodine from existing brine streams will be beneficial in the light of the current weakness in the price of natural gas. The Group's WET® is well suited for the extraction of iodine, gas and oil from these brine streams. All the target operators are producing between 35,000 bbls per day to 300,000 bbls per day per well cluster. Without having the CAPEX associated with the drilling of a production well, injection well, electric infrastructure, brine lines or surface facilities, Iofina is able to have a low cost CAPEX and OPEX model utilizing these different brine streams within our current WET® process and enabling us to  bring on near immediate production. We are working in collaboration with the operators with a view to establishing a working relationship and mutual royalty agreement

Additionally, Iofina's management recognized that due to the current natural gas market weakness, additional acreage in Montana at the Atlantis Prospect could be acquired at significantly reduced land acquisition cost. I am pleased to announce that we have recently acquired further c.230,000 net acres, 17 shut-in wells, c.35 plugged wells that can be re-entered, surface facilities, access roads, pipelines and gathering systems, well and land files, land title opinions, land surveys, engineering dataand extensive seismic coverage over our project area of 2D and 3D proprietary data. The wells were drilled in 2004-2006 but encountered the co-production of iodine rich brine over time and thus were shut-in to avoid dealing with the co-produced water. The recently acquired wells, for which Iofina had previously already leased the iodine rights, will immediately be brought on-line for production, injection wells awaiting approval, clusters designed and WET® units employed to begin production. This acquisition means we have secured nearly all the attractive acreage in the Atlantis Prospect.

We continue to remain excited about Iofina's prospects in 2009 and our ability to continually create value for our shareholders.

Dr. Chris Fay CBE

Non-Executive Chairman

Iofina plc

May 2009 

  FINANCIAL REVIEW

Iofina reported a net gain of £788,729 in the year ended 31 December 2008 (2007: net loss of £394,428). The basic earnings per share was 0.94p and no dividend is being declared.

The Group's most significant financial event of the year was the public market capital financing. Following the decision made late last year to pursue a public listing in London to accelerate Iofina's growth plans, the Group was successfully admitted to AIM market of the London Stock Exchange on 9 May 2008. Iofina simultaneously raised £15.1m before expenses. The Group's unique story and growth potential was well received by the investment community resulting in a significantly oversubscribed placing and a number of new well respected international institutional shareholders becoming shareholders.

In the second half of 2008, the Group initiated the necessary infrastructure for development of the Atlantis Prospect. The Group ended the year with £956,396 in intangible assets (2007: £200,002) and £2.89 million of net property, plant and equipment (2007: nil).

The Group was also able to use funds raised from the IPO to generate £724,178 in interest and investment income (2007: £10,420).

With a net cash inflow from financing activities of £14.1 million, relating to monies raised from the AIM flotation, the Group ended the year well funded with a net cash position of £12.9 million. The Directors believe that this will be sufficient to complete the development of the Atlantis Prospect as set out at the IPO, including taking Iofina into cash generation.

In February 2009 the Company raised £5 million (before expenses) through a placing of 9,090,000 new ordinary shares of 1p each in the Company (the "Placing Shares"), at a price of 55p per share (the "Placing") with respect to vertically integrating Iofina into the iodine derivatives market.

Lance Baller

Finance Director

Iofina plc

May 2009

 

IOFINA PLC

CONSOLIDATED INCOME STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2008

 

Year ended

Year ended

31 December 

31 December

2008

2007

£

£

Continuing operations 

Revenue

-

-

Cost of sales

-

-

Gross loss

-

-

Administrative expenses

(1,243,263)

(400,329)

Finance income

2,071,542

10,420

Finance expense

-

(4,519)

Profit/(Loss) before taxation 

828,279

(394,428)

Taxation

(40,000)

-

Profit/(Loss) for the year attributable to shareholders

788,279

(394,428)

Basic and diluted earnings/(loss) per share (pence)

0.94

(0.65)

  IOFINA PLC

CONSOLIDATED BALANCE SHEET AS AT 31 DECEMBER 2008

Year ended

Year ended

31 December 

31 December

2008

2007

£

£

Assets

Intangible fixed assets

956,396

200,002

Plant, property and equipment 

2,897,674

-

Total non current assets

3,854,070

200,002

Other receivables and repayments

20,728

3,922

Cash and cash equivalents

12,968,678

1,319,281

Total current assets

12,989,406

1,323,203

Total assets 

16,843,476

1,523,205

Liabilities

Trade and other payables

643,524

231,275

Total current liabilities 

643,524

231,275

Equity

Issued share capital

938,161

221,205

Share premium

14,537,403

1,685,233

Share-based payment reserve

516,884

20,025

Accumulated losses

207,907

(580,371)

Foreign currency reserve

(403)

(54,161)

Total equity

16,199,952

1,291,930

Total equity and liabilities

16,843,476

1,523,205

  IOFINA PLC

CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY

Share Capital

£

Share Premium

£

Share-based payment reserve

£

Retained loss

£

Foreign currency 

Reserve

£

Total equity

£

Balance at 1 January 2007

196,000

-

-

(185,944)

(40,232)

(30,176)

Loss for the year

-

-

(394,428)

-

(394,428)

Currency translation adjustment

(13,929)

(13,929)

Net expense recognized directly in equity

-

-

-

(13,929)

(13,929)

Total recognized income and expense for the year

-

-

(394,428)

(13,929)

(408,357)

New share capital subscribed

25,205

1,685,233

-

-

-

1,710,438

Share-based payment reserve

-

-

20,025

-

-

20,025

Balance at 31 December 2007

221,205

1,685,233

20,025

(580,372)

(54,161)

1,291,930

Profit for the year

-

-

788,279

-

788,279

Currency translation adjustment

-

-

-

53,758

53,758

Net income recognized directly in equity

-

-

-

53,758

53,758

Total recognized income and expense for the year

-

-

788,279

53,758

842,037

New share capital subscribed

716,545

14,383,455

-

-

-

15,100,000

Share issue costs

(1,530,874)

(1,530,874)

Share-based payment reserve

-

-

496,859

-

-

496,859

Balance at 31 December 2008

937,750

14,537,814

516,884

207,907

(403)

16,199,952

  IOFINA PLC

CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2008

Year ended

Year ended

31 December

31 December

2008

2007

£

£

Cash flows from operating activities

Profit/(Loss) after taxation

(788,279)

(394,428)

Adjustments for:

Depreciation

19, 887

Investment Income

(724,178)

(10,420)

Interest expense

-

4,519 

Currency translation adjustment

53, 758 

(13,929)

137, 746 

(414,258)

Decrease/(Increase) in other receivables and prepayments

(16,807)

63,045 

Increase in trade and other payables

412,249 

174,542 

Cash used in operations

533,188 

(176,671)

Interest paid

-

(4,519)

Net cash outflow from operating activities

533,188 

(181,190)

Cash flows from investing activities

Interest received

724,178 

10,420 

Acquisition of property, plant and equipment

Acquisition of intangible assets

(2,917,560)

(33,933)

(756,394)

Net cash outflow from investing activities

(2,949,776)

(23,513)

Cash flows from financing activities

Proceeds from the issue of ordinary share capital

15,100,000 

1,487,914 

Cost of issue of ordinary share capital paid

(1,034,015)

(102,225)

Net cash inflow from financing activities

14,065,985 

1,385,689 

Net increase in cash and cash equivalents

11,649,398 

1,180,986 

Cash and cash equivalents at beginning of year

1,319,281 

138,295 

Cash and cash equivalents at end of year

12,968,678 

1,319,281 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1. Accounting Policies

The Company is a public limited company incorporated and domiciled in England.

The registered office is located at 82 St. John StreetLondonEC2M 4JN. The principal activities of the Company are that of investment holding, geological and chemical consulting

 Basis of preparation of financial statements

The consolidated financial statements are presented in pounds sterling and have been prepared on the historical cost basis.

The Group has prepared its financial information under International Financial Reporting Standards as adopted by the European Union. The preparation of financial statements under IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies.

The preparation of financial statements, in conformity with IFRS, requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements including the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on management's best knowledge of current events and actions, actual results may ultimately differ from those estimates.

Going concern assumption

In common with many exploration companies, the Group raises finance for its exploration, appraisal and development activities in discrete tranches. Further funding is raised as and when required. In February 2009, the Company raised an additional £5 million (before expenses) to pursue opportunities in the iodine specialty chemical derivatives market. At its current stage of development, the directors consider that the Group does not need to raise additional funds in order to realise its business plan with respect to the Atlantis Prospect. 

2. Segment reporting

a. Business segments - The Group's only business segment is the exploration for, and development of, natural gas and associated iodine in certain areas of the USA. Business segments are the primary segments of the Group as products and services represent the predominant source and nature of risks and returns.

b. Geographical segments - The Group also reports by geographical segment. All the Group's activities are related to exploration for, and development of, natural gas and associated iodine in certain areas of the USA with support provided by the UK office. In presenting information on the basis of geographical segments, segment assets and the cost of acquiring them are based on the geographical location of the assets. There was no Group turnover in the year.

31 December

31 December

2008

2007

Total assets

£

£

UK 

12,408,466 

1,374,800 

USA

4,435,010 

148,405 

Total

16,843,476 

1,523,205 

Capital expenditures

UK 

-

-

USA

3,673,954 

33,933 

Total

3,673,954 

33,933 

3. Finance income and expense

Year ended

Year ended

31 December

31 December

2008

2007

£

£

Foreign exchange gain

1,347,364 

-

Interest and investment income

724,178 

10,420 

Total

2,071,542

10,420

Interest expense

-

(4,519)

4. Earnings per share

The calculation of earnings per ordinary share is based on a profit after tax of £788,279 (2007: loss £394,428) and the weighted average number of ordinary shares outstanding of 84,113,001 (2007: 60,993,406). The warrants and options are not dilutive and there is, therefore, no difference between the diluted loss per share and the basic loss per share.

  

5. Intangible assets

Deferred

exploration

costs

£

Cost

Balance at 1 January 2007

166,069 

Additions

33,933 

Balance at 31 December 2007

200,002 

Additions

756,394 

Balance at 31 December 2008

956,396 

Accumulated Amortization

Balance at 31 December 2007

-

Additions

-

At 31 December 2008

-

Carrying amounts

At 31 December 2007

200,002 

At 31 December 2008

956,396 

Deferred exploration costs primarily relate to the costs of acquiring leases to explore, drill and produce oil and gas in certain areas of Montana.

Impairment reviews for deferred exploration and evaluation costs are carried out on a project by project basis, with each project representing a potential single cash generating unit. An impairment review is undertaken when indicators of impairment arise. 

6. Cash and cash equivalents

31 December

31 December

2008

2007

£

£

Cash in US Dollar Accounts

6,790,275 

255,993 

Cash in Pound Sterling Accounts

6,178,403 

1,063,288 

Cash at bank

12,968,678 

1,319,281 

7. Post balance sheet events

In February 2009, the Group raised £5 million (before expenses) through a placing of 9,090,000 new ordinary shares of 1p each in the Company (the "Placing Shares"), at a price of 55p per share (the "Placing").The net proceeds of the Placing will be primarily applied to pursue several new opportunities in the iodine specialty chemical derivatives market that have recently emerged. 

8. Publication of non statutory accounts

The summary accounts set out above do not constitute statutory accounts as defined by Section 240 of the UK Companies Act 1985. The summarised consolidated balance sheet at 31 December 2008 and the summarised consolidated income statement, summarised consolidated statement of changes in equity and the summarised consolidated cash flow statement for the year then ended have been extracted from the Group's 2008 statutory financial statements upon which the auditors' opinion is unqualified. The results for the year ended 31 December 2007 have been extracted from the statutory accounts for that period, which contain an auditors' report which is unqualified.

9. Annual Report

The Annual Report for the year ended 31 December 2008 will be posted to shareholders shortly. Copies of the report will be available from the Company's registered office at 82 St. John Street, London EC1M 4JN and also from the Company's website www.iofina.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR SFFEFFSUSEEI
Date   Source Headline
2nd May 20247:00 amRNSFinal Results
16th Apr 20247:00 amRNSQ1 2024 Corporate Update
17th Jan 20247:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSQ4 2023 Corporate Update
30th Nov 20237:00 amRNSIO#9 Update
20th Oct 20237:00 amRNSSigned Agreement for IO#10 and Q3 2023 Update
11th Sep 20237:00 amRNSInterim Results
25th Aug 20235:00 pmRNSHolding(s) in Company
24th Jul 20235:00 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSH1 Update and Updated Loan Facilities
14th Jun 20232:00 pmRNSResult of AGM
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.